Pharmacy benefit manager Express Scripts, part of Cigna's Evernorth subsidiary, will be adding Humira biosimilars to its formulary in 2023 as preferred products, which will be available to patients ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon ...

Express Scripts will prefer the first Food and Drug Administration-approved interchangeable biosimilar product, a move it says will lead to millions in savings. Semglee, which was developed by Viatris ...

Express Scripts, the pharmacy benefits management business of the Cigna Group's Evernorth, will add three additional biosimilars to its National Preferred Formulary that it said will compete with ...

Participating health plans and employers can now expand access to Livongo’s leading Diabetes, Hypertension, and Weight Management solutions Livongo also gains preferred status within the Express ...

About eight month after its unveiling, Express Scripts has now revealed the companies and programs it is including in the inaugural cohort of its digital health formulary — the first such resource ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on rebates ...

The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...

(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen ...

In October, Express Scripts announced that it would add Viatris’ SEMGLEE (insulin glargine-yfgn) injection as a preferred therapy on its formulary beginning in January 2022. Back in July, the FDA ...